Vivani Medical, Inc. - Form 8-K Summary
Business Context and Reporting Period
Company: Vivani Medical, Inc. (VANI)
Filing Date: March 26, 2025
Reporting Period: Event date March 26, 2025; Report date March 27, 2025
Context: The Company entered into a Material Definitive Agreement for a private placement of common stock.
Key Financial Metrics
This filing reports on a financing transaction rather than periodic operating results. Specific metrics include:
- Gross Proceeds: Approximately $8.25 million expected.
- Shares Issued: 7,366,071 shares of common stock.
- Purchase Price: $1.12 per share (last reported sale price on the effective date).
- Transaction Costs: No placement agent or investment banking fees incurred.
- Warrants/Discounts: None provided.
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for current period revenue, profit, or cash flow.
Material Changes and Transaction Structure
The Company agreed to sell shares to an entity beneficially owned by Gregg Williams, Chairman of the Board of Directors. Key structural details include:
- Closing Schedule: The placement is expected to occur over five closing dates through January 15, 2026.
- Conditions: Each closing is subject to the satisfaction or waiver of closing conditions.
- Regulatory Status: Shares issued pursuant to an exemption from registration under Rule 506 of Regulation D and Section 4(a)(2) of the Securities Act.
- Investor Status: Purchaser represented as an "accredited investor" acquiring shares for investment only.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release on March 27, 2025, announcing the $8.25 million private placement equity financing.
Risks and Contingencies:
- Proceeds are contingent upon the satisfaction of closing conditions at each of the five scheduled dates.
- Shares are unregistered and may not be offered or sold in the United States absent registration or an applicable exemption.
- The transaction involves a related party (Chairman of the Board).
Investor Verification Checklist
- Verify the satisfaction of closing conditions for each of the five scheduled closing dates through January 15, 2026.
- Confirm the actual issuance of shares and receipt of proceeds as the transaction unfolds.
- Review the full Share Purchase Agreement (Exhibit 10.1) for specific closing conditions and covenants.
- Monitor for any future filings regarding the resale or registration of these unregistered shares.